Live data · NADAC + Part D CY24 · reviewed daily

Latanoprost (XALATAN)

Prostaglandin Analog class · 8 generic manufacturers · 8 ANDAs filed at FDA.

First FDA approval2010-11-15
Generic availableYes · 8 mfrs
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$204.7M in CY2024 Part D spend16.6M claims · 4.9M beneficiaries · 329 plans surveyed

Lowest NADAC
$1.24/unit
10 NDCs benchmarked, lowest of all strengths.
Average NADAC
$12.18
Across all dosage forms in distribution.
Highest NADAC
$108.34
Wide spread — brand-strength NDCs still in market.
Plans with PA
0 / 329
Zero PA friction across surveyed plans.

Questions a plan sponsor actually asks.

FAQPage schema11 entries indexed · 4 visible
What is Latanoprost used for?

Latanoprost is tracked in Medicare Part D. Specific indication information is not available in our current dataset.

Is there a generic for Latanoprost?

Yes. 8 ANDAs filed at FDA, 8 generic manufacturers currently shipping.

How much does my plan pay for Latanoprost?

Across 329 Part D plans, Latanoprost averages $12.18/unit (NADAC). Lowest available: $1.24/unit. Highest in distribution: $108.34/unit.

Is Latanoprost on the FDA shortage list?

No. Latanoprost is not currently on the FDA Drug Shortage Database.

7 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Sources · every number above traces back.

Last refresh15 Oct 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (10 approvals on file) · NADAC unit costs: CMS NADAC weekly file (10 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.